At a glance
- Originator Bristol-Myers Squibb
- Class Antiallergics; Antiasthmatics; Phenylurea compounds
- Mechanism of Action CCR3 receptor antagonists; Chemokine CCL11 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic rhinitis; Asthma
Most Recent Events
- 23 May 2007 Discontinued - Phase-I for Allergic rhinitis in USA (unspecified route)
- 23 May 2007 Discontinued - Phase-I for Asthma in USA (unspecified route)
- 19 Mar 2001 New profile